Taiho Ventures selected for AMED’s Startup Ecosystem program

2 April 2024

Taiho Pharmaceutical, a subsidiary of Otsuka (TYO: 4578), on Monday revealed that its Taiho Ventures unit has been selected as a certified venture capital of the Strengthening Program for Pharmaceutical Startup Ecosystem implemented by the Japan Agency for Medical Research and Development (AMED) and has entered into an agreement with AMED.

To solve the shortage of fundings for the development of new drugs, this Program supports pharmaceutical start-up for development and commercialization, provided they secure funding from venture capital firms registered by AMED specializing in drug development and providing hands-on business management and commercialization support.

Taiho Ventures not only has one of the largest investment pools ($400 million) among the CVC firms of Japanese pharma companies, but also focuses on delivering cutting-edge technologies and therapies to society by supporting pharmaceutical start-ups while leveraging its experience in research and development and business management, it said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK